Yin, Jiale, Author at MediaMedic

Annual Review | Academician Binghe Xu: Advances in Systemic Therapy for HR+/HER2- Breast Cancer in 2024

By Yin, Jiale 2025.02.10

Editor’s Note: Breast cancer remains the leading cause of cancer-related deaths among women worldwide, with hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer being the most common molecular subtype. In recent years, targeted therapies, antibody-drug conjugates (ADCs), and selective estrogen receptor degraders (SERDs) have propelled this subtype into the era of precision medicine. Looking back at 2024, what breakthroughs and conceptual shifts have occurred in the systemic treatment of HR+/HER2- breast cancer? Oncology Frontier invited Academician Binghe Xu from the Cancer Hospital Chinese Academy of Medical Sciences and the Chinese Academy of Engineering to provide an overview and summary.

Five-Year CheckMate 649 Update: Nivolumab Plus Chemo Extends Survival for Chinese Gastric Cancer Patients

By Yin, Jiale 2025.02.07

Introduction: Gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma are among the most aggressive malignancies, particularly in their advanced stages. The CheckMate 649 trial previously established nivolumab plus chemotherapy as…

Interferon-High Immunophenotype and Immunotherapy Response in Colorectal Cancer

By Yin, Jiale 2025.02.06

A new study published in Cancer Cell, provides key insights into the role of the interferon-high (IFN-high) immunophenotype in predicting response to immune checkpoint inhibition (ICI) in colorectal cancer (CRC). By analyzing tumor microenvironment features, the study identifies a subset of both mismatch repair-deficient (dMMR) and mismatch repair-proficient (pMMR) CRCs that exhibit an IFN-high profile, marked by cytotoxic T cells and antigen-presenting macrophages.

Annual Review | Prof. Jun Ma: 2024 Updates on Guidelines and Advances in Acute Lymphoblastic Leukemia (ALL)

By Yin, Jiale 2025.01.27

In recent years, the field of hematologic oncology has witnessed remarkable breakthroughs, with acute lymphoblastic leukemia (ALL) emerging as a focal point of progress. Chinese researchers have made significant contributions, driving milestone advancements in both research and clinical practice. To usher in the new year, Hematology Frontier invited Professor Jun Ma from the Harbin Institute of Hematology and Oncology to provide an in-depth review of the key developments in ALL during 2024. This comprehensive analysis aims to guide clinical practice and inspire future research.

Gut | Aspirin Use Lowers Pancreatic Cancer Risk and Mortality in Type 2 Diabetes Patients

By Yin, Jiale 2025.01.25

Pancreatic cancer (PC) stands as one of the most lethal cancers globally, ranking 12th in prevalence and sixth in cancer-related deaths. Its aggressive nature and often late diagnosis contribute to a dismal 5-year survival rate of merely 12%. While surgical resection offers the only potential cure, most patients are diagnosed at advanced stages, rendering surgery ineffective. Currently, effective and cost-efficient screening tools for the general population are lacking, and recommended screening strategies, like cross-sectional imaging and endoscopic ultrasonography, are limited to high-risk individuals.

Dr. Kun Wang: Advances in Early Triple-Negative Breast Cancer Treatment—Platinum-Based Therapy, Immunotherapy, and ADCs Breakthroughs | Northern Breast Cancer Salon Annual Progress Review

By Yin, Jiale 2025.01.24

The "Northern Breast Cancer Salon Annual Progress Review" was held from January 3–5, 2025, in Beijing. The conference comprehensively reviewed the latest advances in breast cancer diagnosis, treatment, and research over the past year, delving into the latest findings for various breast cancer subtypes and their impact on clinical practice. The conference also focused on discussions regarding updates to the CSCO BC guidelines, providing scientific guidance for clinical practice in breast cancer. At the event, Oncology Frontier invited Dr. Kun Wang from Guangdong Provincial People's Hospital to review the past year’s advancements in the field of early triple-negative breast cancer (TNBC) treatment.

ESMO ASIA 2024 | Dr. Ken Kato: RATIONALE-305 Confirms the Clinical Benefit of Immunotherapy Plus Chemotherapy as First-Line Treatment for Advanced Gastric Cancer

By Yin, Jiale 2025.01.23

The global multicenter, randomized, double-blind phase III RATIONALE-305 trial, led by Professor Ruihua Xu as the Global Leading PI, demonstrated that tislelizumab combined with chemotherapy significantly improves overall survival (OS) compared to placebo plus chemotherapy in patients with advanced gastric cancer. This study offers a new first-line treatment option for patients with advanced gastric cancer. At the 2024 European Society for Medical Oncology Asia Congress (ESMO ASIA 2024), the analysis of patient-reported outcomes (PROs) for Asian participants was presented. Oncology Frontier spoke with Dr. Ken Kato from the National Cancer Center Hospital in Japan for his insights.

SABCS 2024 | Dr. Jia Wang: Survival Data from Different Chemotherapy Regimens in the WSG-ADAPT HR+/HER2- Study Released

By Yin, Jiale 2025.01.19

At the highly anticipated 2024 San Antonio Breast Cancer Symposium (SABCS), numerous groundbreaking studies in breast cancer treatment were unveiled. Among them, the Working Group for Gynecological Oncology (WSG) presented long-term survival data from the WSG ADAPT-HR+/HER2- early breast cancer chemotherapy cohort (Abstract No.: GS3-04). This study integrates clinical pathology, genomic testing, and endocrine therapy response to refine risk stratification for recurrence in HR+/HER2- patients. Oncology Frontier invited Dr. Jia Wang from The Second Affiliated Hospital of Dalian Medical University to provide insights and commentary on this significant research.

ESMO ASIA 2024 | Dr. Zhizhong Pan’s Team Unveils the Key Role of ADAR1 in Immunotherapy Resistance for Colorectal Cancer

By Yin, Jiale 2025.01.18

In the field of immunotherapy for colorectal cancer (CRC), ADAR1, an essential RNA-editing enzyme, has gained significant attention in recent years. At the 2024 ESMO Asia Congress, Dr. Da Kang from Dr. Zhizhong Pan’s team at the Sun Yat-sen University Cancer Center presented their latest findings on ADAR1 expression in T cells and its impact on immunotherapy resistance in CRC (Abstract No. 95P). Digestive Oncology Frontier interviewed Dr. Da Kang at the conference to delve deeper into this groundbreaking research.

ESMO ASIA 2024 | Dr. Li Zhang: Insights from the BOOSTER Study on EGFR-Mutant NSCLC Treatment

By Yin, Jiale 2025.01.17

Epidermal growth factor receptor (EGFR) gene mutations are the most common oncogenic driver mutations in non-small cell lung cancer (NSCLC) patients in China, with a significantly higher incidence compared to Caucasian populations. At the recent ESMO Asia Congress 2024, Dr. Li Zhang from the Sun Yat-sen University Cancer Center presented results from the Phase II BOOSTER clinical trial investigating Becotarug (JMT101) combined with Osimertinib for the treatment of classic EGFR-mutant NSCLC patients. Oncology Frontier interviewed Professor Zhang to discuss the background and key findings of this study.